Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARGX-213
- Development stage
- Phase 1
- Lead developer
- argenx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
ARGX-213 is an investigational monoclonal antibody developed by argenx that targets the neonatal Fc receptor (FcRn). It acts as an FcRn inhibitor, designed to modulate IgG recycling and reduce pathogenic IgG levels. The drug is being developed as part of argenx’s pipeline focused on immunology and rare diseases, leveraging their expertise in FcRn biology. Preclinical data suggest that ARGX-213 has an increased half-life compared to efgartigimod (another FcRn inhibitor), potentially allowing for extended dosing intervals such as monthly administration. As of mid-2025, it is in Phase 1 clinical trials evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers[3][6][9].
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on ARGX-213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARGX-213.